Insulet Corp. logo
PODDInsulet Corp.

Current vs Average EV/EBITDA Ratio

EV/EBITDA Ratio

How the today ev/ebitda ratio of 18.99x compares to its TTM/3Y/5Y/10Y/15Y/20Y averages as of Thursday, June 25, 2026.

PODD EV/EBITDA Ratio

PODD Current vs Average EV/EBITDA Ratio

PODD EV/EBITDA Ratio vs Average

CURRENT VS TTM AVG

-55.79%

CURRENT VS 3Y AVG

-60.53%

CURRENT VS 5Y AVG

-81.32%

CURRENT VS 10Y AVG

-85.66%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA
5,400 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Ashley A. McEvoy